Scleroderma Diagnostics and Therapeutics Market by Drug Class (Immunosuppressive Agents, Corticosteroids, Endothelin Receptor Agonists, Calcium Channel Blockers, Chelating Agents, PDE-5 Inhibitors, H2 Blockers, Prostacyclin Analogues, ACE Inhibitors, and Proton Pump Inhibitors), by Indication (Systemic and Localized), and by Diagnostic Test Type (Imaging Techniques, Skin Biopsy, Electrocardiogram and Echocardiogram, Pulmonary Function Tests, and Blood Test)-Global Industry Analytics, COVID-19 Business Impact, and Trends, 2020 - 2029

                                          
Abstract
                    
The report covers forecast and analysis for the scleroderma diagnostics and therapeutics market on a global and regional level. The study provides historical data from 2015 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes drivers and restraints for the scleroderma diagnostics and therapeutics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the scleroderma diagnostics and therapeutics market on a global as well as regional level.

In order to give the users of this report a comprehensive view of the scleroderma diagnostics and therapeutics market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein segmental segments are benchmarked based on their market size, growth rate, and general attractiveness.


The report provides company market share analysis in order to give a broader overview of the key players in the scleroderma diagnostics and therapeutics market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new drug class launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the scleroderma diagnostics and therapeutics market on the global and regional basis. 

The study provides a decisive view of the scleroderma diagnostics and therapeutics market by segmenting the market based on drug class, indication, diagnostic test type, and regions. The segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. The drug class segment has been segmented into immunosuppressive agents, corticosteroids, endothelin receptor agonists, calcium channel blockers, chelating agents, PDE-5 inhibitors, H2 blockers, prostacyclin analogs, ACE inhibitors, and proton pump inhibitors. Based on the indication, scleroderma diagnostics and therapeutics market have been segmented into systemic and localized. Based on diagnostic test type, scleroderma diagnostics and therapeutics market have been segmented into imaging techniques, skin biopsy, electrocardiogram and echocardiogram, pulmonary function tests, and blood test.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further bifurcation into major countries including the U.S. Canada, Germany, France, the UK, China, Japan, India, and Brazil. This segmentation includes demand for scleroderma diagnostics and therapeutics based on individual segment and applications in all the regions and countries.

The report also includes detailed profiles of end players such as Bayer AG, Allergan, Inc., Active Biotech AB, BioLineRx, Ltd., Digna Biotech, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Vida Therapeutics Inc., Angion Biomedica Corp., Daval International Ltd., Corbus Pharmaceuticals, Inc., and F. Hoffmann-La Roche Ltd. among others.

This report segments the global scleroderma diagnostics and therapeutics market as follows:

Global Scleroderma Diagnostics and Therapeutics Market: By Drug Class

	Immunosuppressive Agents
	Corticosteroids
	Endothelin Receptor Agonists
	Calcium Channel Blockers
	Chelating Agents
	PDE-5 Inhibitors
	H2 Blockers
	Prostacyclin Analogues
	ACE Inhibitors
	Proton Pump Inhibitors

Global Scleroderma Diagnostics and Therapeutics Market: By Indication

	Systemic
	Localized

Global Scleroderma Diagnostics and Therapeutics Market: By Diagnostic Test Type

	Imaging Techniques
	Skin Biopsy
	Electrocardiogram and Echocardiogram
	Pulmonary Function Tests
	Blood Test

Global Scleroderma Diagnostics and Therapeutics Market: By Region

	North America
	
		The U.S.
	
	
	Europe
	
		UK
		France
		Germany
	
	
	Asia Pacific
	
		China
		Japan
		India
	
	
	Latin America
	
		Brazil
	
	
	The Middle East and Africa